Viatris PT receives Investment Bank Analyst Rating Update
By Andrea Shalal WASHINGTON (Reuters) - U.S. Treasury Secretary Janet Yellen will travel to Senegal, Zambia and South Africa during the next two weeks, as the United States aims...
For the consumer, inflation losing its sharp edge was the story this week. It was a move fuelled mostly by a welcomed drop in gas prices. But for the investor, the positive...
The COVID-19 pandemic highlighted the importance of health care and the role biopharma companies play in drug and vaccine development. As a result, the sector grew tremendously...
It seems like much more than just 11 days ago that St. Louis Fed President James Bullard said the US central bank needed to bump up its short-term interest rate to 1% by July 1....
Viatris Inc. is a global healthcare company. The Company has four segments: Developed Markets, Greater China, JANZ and Emerging Markets. Developed Markets segment comprises its operations primarily in North America and Europe. Greater China segment includes its operations in China, Taiwan and Hong Kong. JANZ segment reflects its operations in Japan, Australia and New Zealand. Emerging Markets segment encompasses its presence in approximately 125 countries with developing markets and emerging economies including in Asia, Africa, Eastern Europe, Latin America and the Middle East, as well as its anti-retroviral franchise. Its portfolio comprises approximately 1,400 approved molecules across a range of key therapeutic areas, including globally recognized iconic and key brands, generics, complex generics, and biosimilars. It operates approximately 40 manufacturing sites worldwide, which produces oral solid doses, injectables, complex dosage forms and active pharmaceutical ingredients.
|Average||13.55 (+11.21% Upside)|
|No. of Analysts||11|